

SEMINARS IN HUMAN AND TRANSLATIONAL IMMUNOLOGY

*Presented by the
Yale Center for Immuno-Oncology*



YaleCME
CONTINUING MEDICAL EDUCATION

“Lessons learned from vaccination of cancer patients”

Lisa Butterfield, PhD

Vice President of Research and Development
Parker Institute for Cancer Immunotherapy

Tuesday, January 5, 2021

4:00 – 5:00pm

Via Zoom – click for [meeting link](#)

By Telephone: 203-432-9666 – Meeting ID: 935 5893 6221 – Psw: HTI

CME credit: Text 22200 to 203-442-9435

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE

The target audience for the HTI Seminar Series comprises attending faculty, clinical and basic scientists, community physicians, nurses, residents, fellows, and students.

NEEDS ASSESSMENT

The HTI Seminar Series seeks to review the scientific basis for choice of immunologically related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and infectious diseases. The goal is to help understand the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice and review the data on the different therapeutic approaches in different specialties.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Understand critical aspects of dendritic cell vaccine biology.
2. Understand critical aspects of human T cell responses.
3. Understand immune suppressive mechanisms of circulating alpha fetoprotein.

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

Lisa Butterfield: Consultant (received consulting fee) for advisory board of: StemImmune/Calidi, SapVax, NextCure, Western Oncolytics, Torque Therapeutics/Repertoire Immune Medicines, Khoris Biosciences, Pyxis Oncology, CytomX, Vir Biotech., Adaptimmune and RAPT.

Carrie Lucas: None

Ellen Foxman: None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

There is no corporate support for this activity

Seminar Host: Marcus Bosenberg, MD, PhD

Course Directors: Carrie Lucas, PhD and Ellen Foxman, MD, PhD

For additional information, please contact Allysia Matthews (allysia.matthews@yale.edu)